BioSpace News Archive

Caliway Biopharmaceuticals (Caliway) today announced the topline results of the CBL-0201EFP Phase 2 study, which met all the primary and secondary efficacy endpoints in the ITT (Intent-to-treat) and PP (per-protocol) analysis population, demonstrating CBL-514’s statistically and clinically significant efficacy in improving cellulite severity with favorable safety and tolerance profiles.

Efforts by the ACC, the AHA, the HFSA, the Heart Rhythm Society and The Society for Cardiovascular Angiography & Interventions to create a new, independent Board of Cardiovascular Medicine under the ABMS are closer to becoming a reality with the creation of a formal Board of Directors and the announcement by the ABMS Advisory Board on Specialty Board Development of an open comment period.

NKGen Biotech, Inc. announced the details disclosed in today’s presentation by Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, entitled “Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01”.

ResMed Inc. announced results for its quarter ended March 31, 2024.

Vincerx Pharma, Inc. announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock.

Ironwood Pharmaceuticals, Inc. announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024.

Bruker Corporation announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024.

Edwards Lifesciences reported financial results for the quarter ended March 31, 2024.

Halozyme Therapeutics, Inc. announced the election of Mahesh Krishnan, M.D. to its Board of Directors.

The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033